英文論文 (2014-2023)【2023】(IF = 20)
1. Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S,
Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R,
Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T.
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus
Bevacizumab Therapy for Hepatocellular Carcinoma.
Cancers (Basel). 2023 May 26;15(11):2927. (IF = 5.2/2022)
2. Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T,
Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M,
Nakagawa H, Nagano H, Takami T, Yamasaki T.
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted
agent-treated hepatocellular carcinoma.
Hepatol Int. 2023 Apr 25. doi: 10.1007/s12072-023-10488-y. (IF = 6.6/2022)
3. Saeki I, Yamasaki T, Yamauchi Y, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H,
Kobayashi K, Kondo T, Ogasawara S, Chiba T, Kawano R, Chayama K, Kato N, Takami T.
Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular
carcinoma undergoing sorafenib therapy.
Cancer Med. 2023 May;12(9):10625-10635. (IF = 4.0/2022)
4. Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D,
Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S,
Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano
K, Nagano H, Takami T.
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treatedwith atezolizumab plus bevacizumab.
Hepatol Res. 2023 Jul;53(7):681-686.

(IF = 4.2/2022)【2022】(IF = 49.7)
1. Suehiro Y, Suenaga S, Kunimune Y, Yada S, Hamamoto K, Tsuyama T, Amano S, Matsui H,
Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Fujimoto Y, Kaino S, Shinjo K, Kondo
Y, Sakaida I, Takami T, Nagano H, Yamasaki T.
CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose StageI Pancreatic Cancer.
Oncology. 2022;100(12):674-684. (IF = 3.5/2022)
2. Fujii T, Nishikawa J, Fukuda S, Kubota N, Nojima J, Fujisawa K, Ogawa R, Goto A, Hamabe

K, Hashimoto S, Wai AP, Iizasa H, Yoshiyama H, Sakai K, Suehiro Y, Yamasaki T, Takami T.
MC180295 Inhibited Epstein-Barr Virus-Associated Gastric Carcinoma Cell Growth by
Suppressing DNA Repair and the Cell Cycle.
Int J Mol Sci. 2022 Sep 13;23(18):10597. (IF = 5.6/2022)
3. Yamaoka Y, Sasai M, Suehiro Y, Hashimoto S, Goto A, Yamamoto N, Suzuki N, Higaki S,
Fujii I, Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y,
Tomochika S, Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Takami T,
Yamasaki T.
Comparison of two primer-probe sets of Fusobacterium nucleatum using droplet digitalpolymerase chain reaction for the detection of colorectal neoplasia from faecal samples.
Ann Clin Biochem. 2022 Nov;59(6):396-403. (IF = 2.2/2022)
4. Yamasaki T, Saeki I, Yamauchi Y, Matsumoto T, Suehiro Y, Kawaoka T, Uchikawa S,
Hiramatsu A, Aikata H, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Takami T, Chayama
K, Kato N, Sakaida I.
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy inPatients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.
Liver Cancer. 2022;11(4):329–40. (IF = 13.8/2022)
5. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri
S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao
K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson
PJ, Arai Y, on behalf of the TACTICS Study Group.
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial
Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone inPatients with Unresectable Hepatocellular Carcinoma.
Liver Cancer. 2022;11(4):354–67. (IF = 13.8/2022)
6. Fukuda S, Nishikawa J, Kobayashi Y, Okabe Y, Fujii T, Kubota N, Otsuyama KI, Tsuneoka
H, Hashimoto S, Suehiro Y, Yamasaki T, Takami T.
The bactericidal effect of far-UVC on ESBL-producing Escherichia coli.
Am J Infect Control. 2022 May 13:S0196-6553(22)00409-6. (IF = 4.9/2022)
7. Fujisawa K, Takami T, Matsumoto T, Yamamoto N, Yamasaki T, Sakaida I.
An iron chelation-based combinatorial anticancer therapy comprising deferoxamine
and a lactate excretion inhibitor inhibits the proliferation of cancer cells.
Cancer Metab. 2022 May 12;10(1):8. (IF = 5.9/2022)【2021】(IF = 32.4)
1. Kobayashi T, Ichihara K, Goda S, Hidaka I, Yamasaki T, Ishida H.

Exploration and time-serial validation of logistic regression models composed ofmultiple laboratory tests for early detection of HCV-associated hepatocellular
carcinoma.
Clin Chim Acta. 2021 Oct;521:137-143. (IF = 5.0/2021)
2. Takahashi H, Okayama N, Natsu Yamaguchi N, Nomura M, Miyahara Y, Mahbub MH, Hase
R, Morishima Y, Suehiro Y, Yamasaki T, Tamada K, Takahashi S, Tojo A, Tanabe T.
Analysis of Relationships between Immune Checkpoint and Methylase Gene
Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation.
Cancers(Basel). 2021 Jun 1; 13(11): 2752. (IF = 5.2/2022)
3. Saeki I, Yamasaki T, Yamauchi Y, Takami T, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata
H, Kawano R, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Chayama K, Kato N, Sakaida
I.
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib
Treatment Failure for Hepatocellular Carcinoma.
Cancers(Basel). 2021 May 7;13(9):2247. (IF = 5.2/2022)
4. Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T,
Takami T, Sakaida I.
Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with
hepatocellular carcinoma.
Clin Nutr. 2021 May;40(5):3585-3591. (IF = 6.3/2022)
5. Yamasaki T, Saeki I, Kotoh-Yamauchi Y, Sasaki R, Tanabe N, OonoT, Matsuda T, Takuro
Hisanaga T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Suehiro Y, Sakaida I.
Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced
Hepatocellular Carcinoma.
Appl Sci(Basel). 2021 Feb 20; 11(4): 1882. (IF = 2.7/2022)
6. Fukuda S, Ito S, Nishikawa J, Takagi T, Kubota N, Otsuyama K, Tsuneoka H, Nojima J,
Harada K, Mishima K, Suehiro Y, Yamasaki T, Sakaida I.
Deep Ultraviolet Light-emitting Diode Light Therapy for Fusobacterium Nucleatum.
Microorganisms. 2021 Feb 19;9(2):430. (IF = 4.5/2022)
7. Fujimoto Y, Suehiro Y, Kaino S, Suenaga S, Tsuyama T, Matsui H, Higaki S, Fujii I, Suzuki
C, Hoshida T, Matsumoto T, Takami T, Nagano H, Sakaida I, Yamasaki T.
Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful
to Diagnose Stage I Pancreatic Cancer.
Oncology. 2021 Jan 13:1-6. (IF = 3.5/2022)【2020】(IF = 76.2)

1. Nishi M, Matsumoto T, Fujisawa K, Suehiro Y, Takami T, Yamamoto N, Yamasaki T, Sakaida
I.
Mesenchymal stem cells induce a fibrolytic phenotype by regulating mmu-miR-6769b5p expression in macrophages.
Stem Cells Dev. 2020 Nov 15;29(22):1457-1466. (IF = 4.0/2022)
2. Takagi T, Nishikawa J, Yanagihara M, Fukuda S, Kubota N, Kobayashi Y, Otsuyama KI,
Nojima J, Tsuneoka H, Sakai K, Suehiro Y, Yamasaki T, Sakurai K, Itatani K, Sakaida I.
Microbicidal effect of deep ultraviolet light-emitting diode irradiation.
Lasers Med Sci. 2020 Sep 9. doi: 10.1007/s10103-020-03143-7. (IF = 2.1/2022)
3. Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Matsuda T, Hisanaga T,
Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I.
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular
Carcinoma Treated with Lenvatinib.
Appl Sci(Basel). 2020 Aug 5;10(16):5403. (IF = 2.7/2022)
4. Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto
N, Yamasaki T, Sakaida I.
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
BMC Cancer. 2020 Jul 22;20(1):681. (IF = 3.8/2022)
5. Ishiguro A, Nishioka M, Morishige A, Kawano R, Kobayashi T, Fujinaga A, Takagi F, Kogo
T, Morikawa Y, Okayama N, Mizuno H, Aihara M, Suehiro Y, Yamasaki T.
What is the best wavelength for the measurement of hemolysis index?
Clin Chim Acta. 2020 Nov;510:15-20. (IF = 5.0/2022)
6. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri
S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K,
Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ,
Arai Y; TACTICS study group.
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE)
plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:
TACTICS trial.
Gut. 2020 Aug;69(8):1492-1501. (IF =24.5/2022)
7. Suehiro Y, Hashimoto S, Goto A, Yamaoka Y, Yamamoto N, Suzuki N, Higaki S, Fujii I,
Suzuki C, Matsumoto T, Hoshida T, Koga M, Tsutsumi T, Lim LA, Matsubara Y, Takami T,
Yoshida S, Hazama S, Yotsuyanagi H, Nagano H, Sakaida I, Yamasaki T.
Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced
Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin.
Clin Transl Gastroenterol. 2020 Jun;11(6):e00176. (IF = 3.6/2022)

8. Hideura E, Suehiro Y, Nishikawa J, Shuto T, Fujimura H, Ito S, Goto A, Hamabe K, Saeki I,
Okamoto T, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Takami T, Sakaida I,
Yamasaki T.
Blood Free-Circulating DNA Testing of Methylated RUNX3 Is Useful for Diagnosing
Early Gastric Cancer.
Cancers (Basel). 2020 Mar 26;12(4):E789. (IF = 5.2/2022)
9. Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, Yokoyama Y, Oishi T,
Maeda M, Kimura T, Kotoh Y, Sasaki R, Miyaji T, Oono T, Aibe Y, Hisanaga T, Iwamoto T,
Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I.
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma
Undergoing Lenvatinib Treatment.
Cancers (Basel). 2020 Mar 25;12(4). pii: E779. (IF = 5.2/2022)
10. Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I,
Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida
I, Yamasaki T.
Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing
Hepatocellular Carcinoma.
Hepatol Commun. 2020 Jan 2;4(3):461-470. (IF = 5.1/2021)
11. Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto
M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K,
Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami
T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T.
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A
Multicenter Study Involving 9,411 Japanese Patients.
Liver Cancer. 2020 Jan;9(1):50-62. (IF = 13.8/2022)
12. Ishikawa T, Sasaki R, Nishimura T, Iwamoto T, Takami T, Yamasaki T, Sakaida I.
Improved Hepatic Reserve and Fibrosis in a Case of "Portal-Systemic Liver Failure"
by Portosystemic Shunt Occlusion.
Am J Case Rep. 2020 Feb 17;21:e921236. (IF = 1.2/2022)【2019】(IF = 31.8)
1.

Shuto T, Nishikawa J, Shimokuri K, Yanagi A, Takagi T, Takagi F, Miura O, Iida M, Nagano
H, Takemoto Y, Harada E, Suehiro Y, Yamasaki T, Okamoto T, Sakaida I.
Establishment of a Screening Method for Epstein-Barr Virus-Associated Gastric
Carcinoma by Droplet Digital PCR.
Microorganisms. 2019 Nov 29;7(12). pii: E628. (IF = 4.5/2022)

2.

Yanagi A, Nishikawa J, Shimokuri K, Shuto T, Takagi T, Takagi F, Kobayashi Y, Yamamoto
M, Miura O, Yanai H, Suehiro Y, Yamasaki T, Yoshiyama H, Sakaida I.
Clinicopathologic Characteristics of Epstein-Barr Virus-Associated Gastric Cancer
Over the Past Decade in Japan.
Microorganisms. 2019 Sep 1;7(9). pii: E305. (IF = 4.5/2022)

3.

Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki
T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N.
Association between polymorphisms in EGFR and tumor response during cetuximab
and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis ofdata from two clinical trials.
Oncol Lett. 2019 Nov;18(5):4555-4562. (IF = 2.9/2022)

4.

Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo
Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N,
Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H.
Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive
markers for the prognosis of resectable colorectal cancer.
Br J Cancer. 2019 Oct;121(8):659-665. (IF = 8.8/2022)

5.

Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T,
Takami T, Sakaida I.
Effect of body composition on survival benefit of hepatic arterial infusion
chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib
therapy.
PLoS One. 2019 Jun 13;14(6):e0218136. (IF = 3.7/2022)

6.

Hanazono T, Hidaka I, Maeda M, Saeki I, Iwamoto T, Ishikawa T, Takami T, Yamasaki T,
Sakaida I.
Utility of Real-time Tissue Elastography in the Sequential Evaluation of Liver Fibrosis
in Patients with Chronic Hepatitis C.
The bulletin of the Yamaguchi Medical School. 2019 Jun;66(1-2):29-35. (IF =NA/2022)

7.

Fukui Y, Saeki I, Matsuda T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I,
Ishikawa T, Takami T, Yamasaki T, Sakaida I.
Utility of Contrast-Enhanced Ultrasonography for the Evaluation of Partial Splenic
Embolization.
The bulletin of the Yamaguchi Medical School. 2019 Jun;66(1-2):7-13. (IF =NA/2022)

8.

Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M, Shuto T, Shimokuri
K, Kanda T, Suehiro Y, Yamasaki T, Sakaida I.
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.

Gastric Cancer. 2019 May;22(3):486-496. (IF = 7.4/2022)【2018】(IF = 50.3)
1. Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I,
Ishikawa T, Takami T, Sakaida I.
No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker ofSorafenib for Hepatocellular Carcinoma.
Liver Cancer. 2018 Oct;7(4):359-371. (IF = 13.8/2022)
2. Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, Yamasaki T, Suzuki N,
Nagano H, Sakamoto J, Mishima H, Nagata N.
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patientswith Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal
Cancer.
J Cancer. 2018 Oct 18;9(22):4092-4098. (IF = 3.9/2022)
3. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I,
Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I.
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic
arterial infusion chemotherapy.
World J Hepatol. 2018 Sep 27;10(9):571-584. (IF = 2.4/2022)
4. Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto
N, Yamasaki T, Sakaida I.
Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreaticcancer cell growth in vitro and in vivo.
Oncotarget. 2018 Jun 19;9(47):28434-28444. (IF = NA/2022)
5. Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M,
Yanai H, Sakai K, Suehiro Y, Yamasaki T, Sakaida I.
Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer.
Cancers (Basel). 2018 May 29;10(6). pii: E167. (IF = 5.2/2022)
6. Suehiro Y, Hashimoto S, Higaki S, Fujii I, Suzuki C, Hoshida T, Matsumoto T, Yamaoka Y,
Takami T, Sakaida I, Yamasaki T.
Blood free-circulating DNA testing by highly sensitive methylation assay to diagnosecolorectal neoplasias.
Oncotarget. 2018 Mar 30;9(24):16974-16987. (IF = NA/2022)
7. Fujisawa K, Takami T, Okada S, Hara K, Matsumoto T, Yamamoto N, Yamasaki T, Sakaida
I.
Analysis of Metabolomic Changes in Mesenchymal Stem Cells on Treatment with

Desferrioxamine as a Hypoxia Mimetic Compared with Hypoxic Conditions.
Stem Cells. 2018 Aug;36(8):1226-1236. (IF = 5.2/2022)
8. Nishioka M, Suehiro Y, Sakai K, Matsumoto T, Okayama N, Mizuno H, Ueno K, Suzuki N,
Hashimoto S, Takami T, Hazama S, Nagano H, Sakaida I, Yamasaki T.
TROY is a promising prognostic biomarker in patients with colorectal cancer.
Oncol Lett. 2018 Apr;15(4):5989-5994. (IF = 2.9/2022)
9. Nishi M, Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I,
Ishikawa T, Takami T, Sakaida I.
Hemobilia immediately after transcatheter arterial chemoembolization using drugeluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion.
Hepatol Res. 2018 Mar;48(4):329-332. (IF = 4.2/2022)
10. Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, Imanaga D, Sakai
K, Matsumoto T, Nishioka M, Takami T, Suzuki N, Hazama S, Nagano H, Sakaida I,
Yamasaki T.
Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese
population.
J Gastroenterol. 2018 Apr;53(4):517-524. (IF = 6.3/2022)
11. Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T,
Takami T, Sakaida I.
Evaluation of the "assessment for continuous treatment with hepatic arterial infusion
chemotherapy" scoring system in patients with advanced hepatocellular carcinoma.
Hepatol Res. 2018 Feb;48(3):E87-E97. (IF = 4.2/2022)
12. Suehiro Y, Zhang Y, Hashimoto S, Takami T, Higaki S, Shindo Y, Suzuki N, Hazama S, Oka
M, Nagano H, Sakaida I, Yamasaki T.
Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal
immunochemical test for haemoglobin is a promising marker for detection of colorectal
neoplasia.
Ann Clin Biochem. 2018 Jan;55(1):59-68. (IF = 2.2/2022)【2017】(IF = 31.4)
1. Takahashi H, Okayama N, Yamaguchi N, Miyahara Y, Morishima Y, Suehiro Y, Yamasaki T,
Tamada K, Takahashi S, Tojo A, Asano S, Tanabe T.
Associations of interactions between NLRP3 SNPs and HLA mismatch with acute andextensive chronic graft-versus-host diseases.
Sci Rep. 2017 Oct 12;7(1):13097. (IF = 4.6/2022)
2. Asada Y, Morimoto Y, Nakaoka Y, Yamasaki T, Suehiro Y, Sugimoto H, Yoshida M, Irahara

M.
Age-specific serum anti-Müllerian hormone concentration in Japanese women and its
usefulness as a predictor of the ovarian response.
Reprod Med Biol. 2017 Sep 18;16(4):364-373. (IF = 3.4/2022)
3. Nishikawa J, Iizasa H, Yoshiyama H, Nakamura M, Saito M, Sasaki S, Shimokuri K,
Yanagihara M, Sakai K, Suehiro Y, Yamasaki T, Sakaida I.
The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer.
Int J Mol Sci. 2017 Jul 25;18(8). pii: E1606. (IF = 5.6/2022)
4. Yamamoto Y, Suehiro Y, Suzuki A, Nawata R, Kawai Y, Inoue R, Hirata H, Matsumoto H,
Yamasaki T, Sasaki K, Matsuyama H.
Germline DNA copy number variations as potential prognostic markers for non-muscle
invasive bladder cancer progression.
Oncol Lett. 2017 Jul;14(1):1193-1199. (IF = 2.9/2022)
5. Nakamura M, Nishikawa J, Saito M, Sakai K, Sasaki S, Hashimoto S, Okamoto T, Suehiro Y,
Yamasaki T, Sakaida I.
Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in
Epstein-Barr virus-associated gastric cancer.
J Med Virol. 2017 Mar;89(3):508-517. (IF = 12.7/2022)
6. Suehiro Y, Sakai K, Nishioka M, Hashimoto S, Takami T, Higaki S, Shindo Y, Hazama S,
Oka M, Nagano H, Sakaida I, Yamasaki T.
Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for
detection of colorectal tumours in a Japanese population.
Ann Clin Biochem. 2017 Jan;54(1):86-91. (IF = 2.2/2022)【2016】(IF = 30.3)
1. Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto
T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I.
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
World J Gastroenterol. 2016 Oct 28;22(40):8967-8977. (IF = 4.3/2022)
2. Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I.
Supportive therapies for prevention of hepatocellular carcinoma recurrence andpreservation of liver function.
World J Gastroenterol. 2016 Aug 28;22(32):7252-63. (IF = 4.3/2022)
3. Harima H, Kaino S, Takami T, Shinoda S, Matsumoto T, Fujisawa K, Yamamoto N, Yamasaki
T, Sakaida I.
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against

pancreatic cancer in vitro and in vivo.
BMC Cancer. 2016 Aug 31;16:702. (IF = 3.8/2022)
4. Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S,
Sakaida I.
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects ofsorafenib.
J Clin Biochem Nutr. 2016 May;58(3):202-9. (IF = 2.4/2022)
5. Fujisawa K, Terai S, Takami T, Yamamoto N, Yamasaki T, Matsumoto T, Yamaguchi K,
Owada Y, Nishina H, Noma T, Sakaida I.
Modulation of anti-cancer drug sensitivity through the regulation of mitochondrial
activity by adenylate kinase 4.
J Exp Clin Cancer Res. 2016 Mar 16;35:48. (IF = 11.3/2022)
6. Urata Y, Yamasaki T, Saeki I, Iwai S, Kitahara M, Sawai Y, Tanaka K, Aoki T, Iwadou S,
Fujita N, Nakayama Y, Maeshiro T, Takami T, Sakaida I.
Clinical characteristics and prognosis of non-B non-C hepatocellular carcinoma
patients with modest alcohol consumption.
Hepatol Res. 2016 Mar;46(5):434-42. (IF = 4.2/2022)【2015】(IF = 6.6)
1. Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T,
Takami T, Yamamoto N, Uchida K, Terai S, Sakaida I.
A new therapeutic assessment score for advanced hepatocellular carcinoma patients
receiving hepatic arterial infusion chemotherapy.
PLoS One. 2015 May 20;10(5):e0126649. (IF = 3.7/2022)
2. Zhang Y, Suehiro Y, Shindo Y, Sakai K, Hazama S, Higaki S, Sakaida I, Oka M, Yamasaki T.
Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer.
Oncol Lett. 2015 Jan;9(1):454-458. (IF = 2.9/2022)【2014】(IF = 58.7)
1. Nishikawa J, Yoshiyama H, Iizasa H, Kanehiro Y, Nakamura M, Nishimura J, Saito M,
Okamoto T, Sakai K, Suehiro Y, Yamasaki T, Oga A, Yanai H, Sakaida I.
Epstein-barr virus in gastric carcinoma.
Cancers (Basel). 2014 Nov 7;6(4):2259-74. (IF = 5.2/2022)
2. Ooishi T, Saeki I, Yamasaki T, Sakaida I.
Hepatocellular carcinoma-induced hemobilia.
Intern Med. 2014;53(14):1579. (IF= 1.2/2022)

3. Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki
T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M.
A novel system for predicting the toxicity of irinotecan based on statistical patternrecognition with UGT1A genotypes.
Int J Oncol. 2014 Oct;45(4):1381-90. (IF = 5.2/2022)
4. Marumoto M, Yamasaki T, Marumoto Y, Saeki I, Harima Y, Urata Y, Hidaka I, Ishikawa T,
Takami T, Segawa M, Yamaguchi Y, Uchida K, Terai S, Sakaida I.
Systemic gemcitabine combined with hepatic arterial infusion chemotherapy withcisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepaticcholangiocarcinoma: a pilot study.
Hepatogastroenterology. 2014 Jan-Feb;61(129):162-7. (IF = NA/2022)
5. Ishikawa T, Shiratsuki S, Matsuda T, Iwamoto T, Takami T, Uchida K, Terai S, Yamasaki T,
Sakaida I.
Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistancein cirrhotic patients with portal hypertension.
J Gastroenterol. 2014 Sep;49(9):1333-41. (IF = 6.3/2022)
6. Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, Marumoto Y, Hidaka I, Urata
Y, Ishikawa T, Takami T, Segawa M, Uchida K, Terai S, Kunitugu I, Tanabe T, Sakaida I.
Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liverdisease.
Hepatol Res. 2014 Oct;44(10):E54-62. (IF = 4.2/2022)
7. Inoue Y, Hazama S, Iwamoto S, Miyake Y, Matsuda C, Tsunedomi R, Okayama N, Hinoda Y,
Yamasaki T, Suehiro Y, Yoshino S, Sakamoto J, Mishima H, Oka M.
FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy inmetastatic colorectal cancer.
Mol Diagn Ther. 2014 Oct;18(5):541-8. (IF = 4.0/2022)
8. Terai S, Takami T, Yamamoto N, Fujisawa K, Ishikawa T, Urata Y, Tanimoto H, Iwamoto T,
Mizunaga Y, Matsuda T, Oono T, Marumoto M, Burganova G, Fernando Quintanilha L,
Hidaka I, Marumoto Y, Saeki I, Uchida K, Yamasaki T, Tani K, Taura Y, Fujii Y, Nishina H,
Okita K, Sakaida I.
Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells
and mesenchymal cells.
Tissue Eng Part B Rev. 2014 Jun;20(3):206-10. (IF = 6.4/2022)
9. Zaitsu J, Yamasaki T, Saeki I, Harima Y, Iwamoto T, Harima Y, Matsumoto T, Urata Y, Hidaka
I, Marumoto Y, Ishikawa T, Takami T, Yamamoto N, Kaino S, Uchida K, Terai S, Sakaida I.
Serum transferrin as a predictor of prognosis for hepatic arterial infusion

chemotherapy in advanced hepatocellular carcinoma.
Hepatol Res. 2014 May;44(5):481-90. (IF = 4.2/2022)
10. Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino
S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M.
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic
lymphocytes plus gemcitabine for unresectable pancreatic cancer.
J Transl Med. 2014 Jun 19;12:175. (IF = 7.4/2021)
11. Yamasaki T, Saeki I, Sakaida I.
Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy inadvanced hepatocellular carcinoma patients refractory to current treatments.
Hepatol Int. 2014 Sep;8 Suppl 2:492-8. (IF = 6.6/2021)